CCL22MP

CCL22MP is an experimental sustained-release formulation consisting of recombinant C-C motif chemokine ligand 22 (CCL22) encapsulated within polymeric microparticles. The microparticles are engineered from a blend of PEG-terminated poly(lactic-co-glycolic acid) (PLGA) and RG502H polymers to provide an initial chemotactic signal followed by a stable, long-term gradient. Administered intramuscularly following skeletal muscle injury, the therapy acts as an agonist for the C-C chemokine receptor type 4 (CCR4), specifically recruiting regulatory T cells (Tregs) to the site of injury. This targeted recruitment modulates the local immune response by promoting the conversion of pro-inflammatory M1 macrophages to anti-inflammatory, pro-regenerative M2 macrophages, thereby reducing the area of injury and enhancing functional strength recovery. Preclinical studies in murine models have demonstrated significant improvements in limb function and muscle healing.

Other names

CCL22-loaded microparticlesCCL-22-loaded microparticlesCCL 22-loaded microparticlesCCL22-releasing microparticlesCCL-22-releasing microparticlesCCL 22-releasing microparticlesCCL22-PLGA microparticlesCCL-22-PLGA microparticlesCCL 22-PLGA microparticlesc-c motif chemokine ligand 22-polymeric microparticles